Baricitinib is First JAK-Inhibitor to Demonstrate Hair Regrowth in Phase 3 Alopecia Areata (AA) Trial
- Wednesday, March 3, 2021, 7:02
- Finance
- Add a comment
INDIANAPOLIS, March 3, 2021 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ:INCY) announced today top-line results from BRAVE-AA2, a Phase 3 study evaluating the efficacy and safety of once-daily baricitinib 2-mg and 4-mg in adults with severe alopecia areata (AA)….
About the Author
adminasapcorp has written 39590 stories on this site.